Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade

Adel Alblihy(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Mashael Algethami(University of Nottingham), Shatha Alqahtani(University of Nottingham), Anna M. Grabowska(Silesian University of Technology), Katia A. Mesquita(University of Nottingham), Ahmed Shoqafi(University of Nottingham), Paloma Ordóñez‐Morán(University of Nottingham), Jennie N. Jeyapalan(University of Nottingham), Alison Ritchie(University of Nottingham), Edgar Hartsuiker(Bangor University), Reem Ali(Hamad bin Khalifa University), Martina Salerno(Bangor University), Nigel P. Mongan(University of Nottingham), Michael S. Toss(Nottingham City Hospital), Lodewijk V. Dekker(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
International Journal of Molecular Sciences
June 30, 2023
10.3390/ijms241310966
Cited by 4

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
|Nature Genetics|2016|439
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374